A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA.

Trial Profile

A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms AVERT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Jun 2017 Results (n=337) of post hoc analysis assessing the proportion of patients achieving remission at month 12 by baseline MRI detected inflammation status and treatment group, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post hoc analysis of AVERT trial evaluating predictors of clinical relapse at month 18 and month 24 after treatment withdrawal presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post hoc analysis assessing the relationship between changes in anti-CarP isotypes and rates of seroconverson to negative in patients with early rheumatoid arthritis, presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top